Enhanced activation of NAD(P)H: Quinone oxidoreductase 1 attenuates spontaneous hypertension by improvement of endothelial nitric oxide synthase coupling via tumor suppressor kinase liver kinase B1/adenosine 5′-monophosphate-activated protein kinase-mediated guanosine 5′-triphosphate cyclohydrolase 1 preservation

Journal of Hypertension

Volumn 32, Issue 2, 2014, Pages 306-317

  Kim, Yong Hoon ^a   Hwang, Jung Hwan ^a   Kim, Kyung Shim ^a   Noh, Jung Ran ^a   Gang, Gil Tae ^a   Oh, Won Keun ^b   Jeong, Kyeong Hoon ^c   Kwak, Tae Hwan ^d   Choi, Hueng Sik ^e   Lee, In Kyu ^f   Lee, Chul Ho ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Seoul National University   (South Korea)

^c Gachon University   (South Korea)

^d KT and G Life Sciences R and D Center   (South Korea)

^e Chonnam National University   (South Korea)

^f Kyungpook National University School of Medicine   (South Korea)

Author keywords

endothelial nitric oxide synthase; guanosine 5 triphosphate cyclohydrolase 1; hypertension; NAD(P)H:quinone oxidoreductase 1; tumor suppressor kinase liver kinase B1 adenosine 5 monophosphateactivated protein kinase

Indexed keywords

ADENOSINE 5 MONOPHOSPHATE ACTIVATED PROTEIN KINASE; ADENOSINE 5' MONOPHOSPHATE ACTIVATED PROTEIN KINASE MEDIATED GUANOSINE 5' TRIPHOSPHATE CYCLOHYDROLASE 1; BETA LAPACHONE; CYCLIC GMP; DIHYDROBIOPTERIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANOSINE TRIPHOSPHATE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRIC OXIDE; PROTEIN KINASE LKB1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SIRTUIN 1; TETRAHYDROBIOPTERIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTIC ENDOTHELIAL CELL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DEACETYLATION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; PRESERVATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TUMOR SUPPRESSOR GENE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BLOOD PRESSURE; CELL LINE; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME ACTIVATION; GTP CYCLOHYDROLASE; HUMANS; HYPERTENSION; MALE; MICE; NAD; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, INBRED SHR; SIRTUIN 1; VASODILATION;

EID: 84892985432     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000018     Document Type: Article

References (61)

1. Brown MJ. Hypertension and ethnic group. BMJ 2006; 332:833-836.
2. Jones DW, Hall JE. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension 2004; 43:1-3.
3. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich) 2010; 12:869-878.
4. Khanna A, Lefkowitz L, White WB. Evaluation of recent fixed-dose combination therapies in the management of hypertension. Curr Opin Nephrol Hypertens 2008; 17:477-483.
5. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376.
6. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84:9265-9269.
7. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86:3375-3378.
8. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res 1999; 43:521-531.
9. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endo-thelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111:1201-1209.
10. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998; 95:9220-9225.
11. Verhaar MC, Westerweel PE, van Zonneveld AJ, Rabelink TJ. Free radical production by dysfunctional eNOS. Heart 2004; 90:494-495.
12. Sugiyama T, Levy BD, Michel T. Tetrahydrobiopterin recycling, a key determinant of endothelial nitric-oxide synthase-dependent signaling pathways in cultured vascular endothelial cells. J Biol Chem 2009; 284:12691-12700.
13. Franscini N, Bachli EB, Blau N, Fischler M, Walter RB, Schaffner A, et al. Functional tetrahydrobiopterin synthesis in human platelets. Circulation 2004; 110:186-192.
14. Cai S, Alp NJ, McDonald D, Smith I, Kay J, Canevari L, et al. GTP cyclohydrolase I gene transfer augments intracellular tetrahydro-biopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc Res 2002; 55:838-849.
15. Wang S, Xu J, Song P, Wu Y, Zhang J, Chul Choi H, et al. Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. Hypertension 2008; 52:484-490.
16. Lee CK, Han JS, Won KJ, Jung SH, Park HJ, Lee HM, et al. Diminished expression of dihydropteridine reductase is a potent biomarker for hypertensive vessels. Proteomics 2009; 9:4851-4858.
17. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1:15-25.
18. Wang S, Xu J, Song P, Viollet B, Zou MH. In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I. Diabetes 2009; 58:1893-1901.
19. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2:28.
20. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005; 2:9-19.
21. Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 2008; 283:27628-27635.
22. Zu Y, Liu L, Lee MY, Xu C, Liang Y, Man RY, et al. SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res 2010; 106:1384-1393.
23. Zheng Z, Chen H, Li J, Li T, Zheng B, Zheng Y, et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 2012; 61:217-228.
24. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:-quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000; 129:77-97.
25. Pardee AB, Li YZ, Li CJ. Cancer therapy with beta-lapachone. Curr Cancer Drug Targets 2002; 2:227-242.
26. Kim YH, Hwang JH, Noh JR, Gang GT, Kim DH, Son HY, et al. Activation of NAD(P)H:quinone oxidoreductase ameliorates spontaneous hypertension in an animal model via modulation of eNOS activity. Cardiovasc Res 2011; 91:519-527.
27. Kim YH, Hwang JH, Kim KS, Noh JR, Gang GT, Kim SW, et al. NQO1 activation regulates angiotensin-converting enzyme shedding in spontaneously hypertensive rats. Cardiovasc Res 2013; 99:743-750.
28. Kim YH, Hwang JH, Noh JR, Gang GT, Tadi S, Yim YH, et al. Prevention of salt-induced renal injury by activation of NAD(P)H:quinone oxidoreductase 1, associated with NADPH oxidase. Free Radic Biol Med 2012; 52:880-888.
29. Seok Y, Kim JI, Ito M, Kureishi Y, Nakano T, Kim SO, et al. Heat shock-induced augmentation of vascular contractility is independent of rho-kinase. Clin Exp Pharmacol Physiol 2006; 33:264-268.
30. Fiege B, Ballhausen D, Kierat L, Leimbacher W, Goriounov D, Schircks B, et al. Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. Mol Genet Metab 2004; 81:45-51.
31. Brandes RP, Kim D, Schmitz-Winnenthal FH, Amidi M, Godecke A, Mulsch A, et al. Increased nitrovasodilator sensitivity in endothelial nitric oxide synthase knockout mice: role of soluble guanylyl cyclase. Hypertension 2000; 35:231-236.
32. Crabtree MJ, Tatham AL, Al-Wakeel Y, Warrick N, Hale AB, Cai S, et al. Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP cyclohydrolase I expression. J Biol Chem 2009; 284:1136-1144.
33. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004; 305:1010-1013.
34. Kjeldsen SE, Messerli FH, Chiang CE, Meredith PA, Liu L. Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin 2012; 28:1685-1697.
35. Gradman AH. Strategies for combination therapy in hypertension. Curr Opin Nephrol Hypertens 2012; 21:486-491.
36. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854-865.
37. Andujar-Plata P, Pi-Sunyer X, Laferrere B. Metformin effects revisited. Diabetes Res Clin Pract 2012; 95:1-9.
38. 2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2005; 2:21-33.
39. Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M, et al. MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J 2003; 22:5102-5114.
40. Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem 2006; 75:137-163.
41. Sasaki S, Higashi Y, Nakagawa K, Kimura M, Noma K, Hara K, et al. A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension. Am J Hypertens 2002; 15:302-309.
42. Raitakari M, Ilvonen T, Ahotupa M, Lehtimaki T, Harmoinen A, Suominen P, et al. Weight reduction with very-low-caloric diet and endothelial function in overweight adults: role of plasma glucose. Arterioscler Thromb Vasc Biol 2004; 24:124-128.
43. Dolinsky VW, Morton JS, Oka T, Robillard-Frayne I, Bagdan M, Lopaschuk GD, et al. Calorie restriction prevents hypertension and cardiac hypertrophy in the spontaneously hypertensive rat. Hypertension 2010; 56:412-421.
44. Trott DW, Gunduz F, Laughlin MH, Woodman CR. Exercise training reverses age-related decrements in endothelium-dependent dilation in skeletal muscle feed arteries. J Appl Physiol 2009; 106:1925-1934.
45. Walsh JH, Bilsborough W, Maiorana A, Best M, O'Driscoll GJ, Taylor RR, et al. Exercise training improves conduit vessel function in patients with coronary artery disease. J Appl Physiol 2003; 95:20-25.
46. Palacios OM, Carmona JJ, Michan S, Chen KY, Manabe Y, Ward JL, et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging (Albany, NY) 2009; 1:771-783.
47. Sriwijitkamol A, Coletta DK, Wajcberg E, Balbontin GB, Reyna SM, Barrientes J, et al. Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes 2007; 56:836-848.
48. Ford RJ, Rush JW. Endothelium-dependent vasorelaxation to the AMPK activator AICAR is enhanced in aorta from hypertensive rats and is NO and EDCF dependent. Am J Physiol Heart Circ Physiol 2011; 300:H64-75.
49. Goirand F, Solar M, Athea Y, Viollet B, Mateo P, Fortin D, et al. Activation of AMP kinase alpha1 subunit induces aortic vasorelaxation in mice. J Physiol 2007; 581:1163-1171.
50. Bordone L, Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol 2005; 6:298-305.
51. Elliott PJ, Jirousek M. Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs 2008; 9:371-378.
52. Ferrara N, Rinaldi B, Corbi G, Conti V, Stiuso P, Boccuti S, et al. Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res 2008; 11:139-150.
53. Canto C, Auwerx J. Calorie restriction: is AMPK a key sensor and effector? Physiology (Bethesda) 2011; 26:214-224.
54. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009; 458:1056-1060.
55. Guyton AC, Coleman TG, Granger HJ. Circulation: overall regulation. Annu Rev Physiol 1972; 34:13-46.
56. Hall JE, Guyton AC, Coleman TG, Mizelle HL, Woods LL. Regulation of arterial pressure: role of pressure natriuresis and diuresis. Fed Proc 1986; 45:2897-2903.
57. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003; 289:2083-2093.
58. Lefevre M, Redman LM, Heilbronn LK, Smith JV, Martin CK, Rood JC, et al. Caloric restriction alone and with exercise improves CVD risk in healthy nonobese individuals. Atherosclerosis 2009; 203:206-213.
59. Guarente L. Mitochondria- A nexus for aging, calorie restriction, and sirtuins? Cell 2008; 132:171-176.
60. Chen D, Bruno J, Easlon E, Lin SJ, Cheng HL, Alt FW, et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev 2008; 22:1753-1757.
61. White AT, Schenk S. NAD+/NADH and skeletal muscle mitochondrial adaptations to exercise. Am J Physiol Endocrinol Metab 2012; 303:E308-E321.